Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals

robot
Abstract generation in progress

Allspring Global Investments increased its stake in Regeneron Pharmaceuticals by 40.1% in Q4 2025, now owning 37,559 shares valued at $29.157 million. This move signals the investment firm’s continued confidence in Regeneron’s growth prospects, innovative drug pipeline, and ability to deliver long-term shareholder value. Regeneron is highlighted as a leading biotech firm known for its drug discovery and biologic therapies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin